secwatch.observer — SEC 8-K summary
======================================

Issuer:     Day One Biopharmaceuticals, Inc. (—)
CIK:        0001845337
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-046522
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Day One Biopharmaceuticals amends bylaws for universal proxy rules and DGCL updates
--------------------------------------------------------------------------------

- Bylaws revised to comply with SEC universal proxy rules (Rule 14a-19) and recent Delaware law changes.
- Advance notice provisions updated: additional disclosures, nominee interview requirement, proxy card color rule.
- Stockholders using universal proxy must certify compliance and provide evidence 5 business days before meeting.
- Emergency bylaw provision added to allow Board quorum during crises.
- Changes effective Feb 17, 2023; no impact on financials or operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/0001193125-23-046522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/d467705d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-046522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer